​PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the Overlooked Small Cap Stocks to Buy Now. Wall Street is positive on PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ahead of its fiscal Q4 2025 earnings, expected to be released on February 24, 2026. The Street expects the company to post quarterly revenue of around $372.87 million and a GAAP EPS of $1.56. ​Recently, on January 26, Ryan Zimmerman from BTIG maintained a Hold rating on the stock without disclosing any price targets. Earlier on Decemb ...

SAN JOSE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at two upcoming investor conferences in March. TD Cowen 46th Annual Health Care Conference Location – Boston, MAFireside Chat – Monday, March 2nd at 11:40am ET 2026 Leerink Global Health Care Conference Location – Miami, FLFireside Chat – ...

As filed with the Securities and Exchange Commission on February 2, 2026 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SS INNOVATIONS INTERNATIONAL, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Florida 3841 47-3478854 (I.R.S. Employer Identification No.) 405, 3 Floor, iLabs Info Technology Centre Udyog Vi ...

Core Insights - SS Innovations International, Inc. has appointed Milan Rao as the Global Chief Operating Officer and Chief Financial Officer to enhance global growth and operational scale in affordable robotic surgery [2][3][5] Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible to a larger global population [2][9] - The company’s product offerings include the proprietary "SSi Mantra" surgical robotic system and the "SSi Mudra" surgical instruments, which support various robotic surgical procedures, including cardiac surgery [9][10] Leadership Appointment - Milan Rao brings over 30 years of executive leadership experience, particularly in technology-enabled transformation and operational efficiency across various industries, including healthcare [4][6] - Rao will succeed Naveen Kumar Amar as CFO, who resigned for personal reasons, and will work closely with the executive leadership team during the transition [3][5] Strategic Goals - The appointment of Milan Rao reflects the company's commitment to attracting top talent to expand the global footprint of its advanced, cost-effective surgical robotic systems [5][6] - Rao is expected to play a crucial role in defining the company's growth strategy and enhancing operational readiness for long-term value creation [6]

Core Viewpoint - SS Innovations International, Inc. has appointed Milan Rao as the Global Chief Operating Officer and Chief Financial Officer, a newly created position, succeeding Naveen Kumar Amar who resigned for personal reasons [1][2]. Company Overview - SS Innovations is focused on developing innovative surgical robotic technologies aimed at making robotic surgery affordable and accessible globally [5]. - The company's flagship product is the "SSi Mantra" surgical robotic system, which is designed to support various robotic surgical procedures, including cardiac surgery [5][6]. Leadership Appointment - Milan Rao brings over 30 years of executive leadership experience, particularly in technology-enabled transformation and operational efficiency across various industries, including healthcare [2]. - Rao has held significant roles in global companies, including Chief Operating Officer and Chief Revenue Officer at Markets and Markets, and has experience in managing operations, financial statements, M&A activities, and capital allocation strategies [2][3]. Strategic Vision - The appointment of Milan Rao is seen as a commitment to attracting top talent to enhance the executive team and expand the global footprint of the SSi Mantra surgical robotic system [3]. - Rao expressed enthusiasm about contributing to the company's strategic direction and operational readiness, emphasizing the potential for long-term value creation [3]. Product Features - The SSi Mantra system features a modular design with 3 to 5 robotic arms, an ergonomic surgeon command center, and advanced imaging capabilities, including a large 3D 4K monitor [6]. - The system has been clinically validated in India for over 100 different types of surgical procedures, showcasing its versatility and effectiveness [6].

Company Overview - Procept BioRobotics Corporation (NASDAQ:PRCT) is a surgical robotics company focused on developing transformative solutions in urology both in the US and internationally [4]. Analyst Ratings and Price Targets - Truist analyst Richard Newitter lowered the price target on Procept BioRobotics to $47 from $50 while maintaining a Buy rating, indicating optimism about the MedTech sector despite caution regarding capital allocation [1]. - UBS analyst Danielle Antalffy initiated coverage with a Buy rating and a price target of $62, citing confidence in the company's growth potential through 2026 and 2027 based on consultations with key opinion leaders [2]. - Bank of America downgraded Procept BioRobotics to Neutral from Buy with a reduced price target of $38, down from $55, highlighting concerns over slowing utilization growth and operational challenges [3]. Market Potential and Growth Drivers - Procept's aquablation technology is noted for its significant market potential in treating benign prostatic hyperplasia, although there are concerns about the simultaneous slowdown in system sales and procedure volume [3]. - The company is focusing on initiatives to increase usage of its current hardware and exploring new system placements in untapped markets, which could drive long-term revenue growth [2]. Industry Context - The MedTech sector is viewed as potentially acting as a source of funds rather than a primary destination for new capital, with a preference for companies that have specific catalysts for growth [1].

Core Insights - Three Chinese technology firms debuted successfully, raising a total of $1.19 billion, which supports Beijing's ambition to enhance its competitiveness in high-tech sectors against the U.S. [1][3] - All three companies experienced significant increases in their stock prices on debut, indicating strong market interest [1][2] Company Summaries - Zhipu AI, an artificial intelligence company, opened 3.3% higher than its offer price of HK$116.20, trading around HK$126.00. It raised HK$4.35 billion, valuing the company at approximately HK$51 billion, with plans to allocate most proceeds for research and development [1][4] - Shanghai Iluvatar CoreX, a semiconductor firm, started trading at 31.6% above its offer price of HK$144.60, reaching around HK$162.50 [2] - Shenzhen Edge Medical, a surgical robotics company, jumped 36.4% above its offer price of HK$43.24, trading at around HK$56.00 [2] Industry Context - The successful listings of these firms come as Chinese authorities expedite AI and semiconductor listings to create domestic alternatives to advanced U.S. technology [3] - Companies like Huawei's AI server spin-off xFusion and memory chipmaker ChangXin Memory Technologies are also preparing for IPOs, indicating a broader trend in the tech sector [3] - Zhipu AI has been recognized as a leading player in China's AI sector, with its CEO noting that the company's overseas expansion is part of normal business operations [5]

Core Insights - Three Chinese technology firms debuted successfully in Hong Kong, raising a total of HK$9.3 billion ($1.19 billion), indicating a positive outlook for new listings in the region [1][5] - All debuting companies traded above their offer prices, with Zhipu AI opening 3.3% higher, Shanghai Iluvatar CoreX rising 31.6%, and Shenzhen Edge Medical increasing by 36.4% [1][2] Company Summaries - Zhipu AI, an artificial intelligence company, raised HK$4.35 billion at an offer price of HK$116.20, achieving a valuation of approximately HK$51 billion. The majority of the proceeds will be allocated for research and development [3][4] - Shanghai Iluvatar CoreX, a semiconductor firm specializing in general-purpose GPUs, raised HK$3.48 billion with an offer price of HK$144.60, resulting in a market capitalization of around HK$36.8 billion. The funds will primarily support R&D in chips, accelerators, and software [4] - Shenzhen Edge Medical, a surgical robotics company, raised about HK$1.12 billion, which will be used for R&D, commercialization, manufacturing capacity, and strategic acquisitions. Key investors include Abu Dhabi Investment Authority and Tencent [5] Market Context - The recent debuts are part of a broader initiative by Chinese authorities to accelerate AI and chip listings, aiming to bolster domestic alternatives to advanced U.S. technology [2] - The performance of these companies will be crucial in determining if Hong Kong can maintain the momentum from last year's IPO resurgence, which saw $37.2 billion raised from 115 new listings, the highest since 2021 [5][6] Upcoming Listings - The IPO pipeline is expanding, with MiniMax Group and OmniVision Integrated Circuits set to begin trading soon, indicating continued interest in the tech sector [6]

Core Insights - Lux Capital has closed a $1.5 billion ninth fund, marking the largest fund in the firm's history [1] - Despite a decline in new VC funds raised in the U.S. to a 10-year low in 2025, limited partners continue to invest in Lux Capital [1] Investment Focus - The firm has a history of investing in defense technologies, which have become highly sought after due to recent geopolitical shifts [2] - Lux was an early investor in Anduril, valued at $30.5 billion, and Applied Intuition, valued at $15 billion, both of which have secured significant contracts with the Pentagon [2] AI Investments - Lux has made early investments in AI startups prior to the industry's rapid growth following the launch of ChatGPT [3] - Notable early-stage AI investments include Hugging Face, Runway AI, and MosaicML, the latter of which was acquired by Databricks for $1.3 billion in 2023 [3] Exits and Performance - The firm has achieved significant exits from investments, including Recursion Pharmaceuticals, which went public in 2021, and Auris Health, sold to Johnson & Johnson for up to $6 billion in 2019 [4] - The latest fundraising effort has increased Lux's total assets under management to $7 billion [4]

Core Insights - Vicarious Surgical Inc. has entered into a strategic partnership with a global digital engineering and software development firm to enhance its robotic surgery technology and operational efficiency [1][2][3] Company Overview - Founded in 2014, Vicarious Surgical is focused on developing innovative surgical robotics aimed at improving surgical efficiency, patient outcomes, and reducing healthcare costs [4] - The company utilizes proprietary human-like surgical robots to perform minimally invasive surgeries [4] - Vicarious Surgical has received backing from notable investors including Bill Gates and Khosla Ventures [4] Strategic Partnership - The external engineering partner will take on a significant portion of software development for the Vicarious Surgical robotic system, including control systems and visualization [2] - This partnership is expected to enhance development velocity, improve milestone predictability, and lower structural costs [2][3] - The new hybrid structure will allow internal teams to focus on core innovation and system integration, facilitating progress towards design freeze and clinical readiness [3] Operational Transformation - The engagement is part of a broader transformation of the company's operating model aimed at improving execution and reducing operating expenses [1][3] - A structured transition plan is in place to ensure continuity across all active workstreams during the onboarding of the external partner [3] - The combination of internal leadership and external execution capacity is anticipated to support more predictable progress towards key milestones [3]